StockNews.AI
QURE
StockNews.AI
7 hrs

QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm

1. uniQure's BLA submission for AMT-130 facing significant FDA challenges. 2. Company stock plummeted over 50% following negative FDA feedback. 3. Kessler Topaz investigating potential federal securities law violations. 4. Timing for AMT-130 regulatory approval now unclear for uniQure.

4m saved
Insight
Article

FAQ

Why Very Bearish?

The 50% stock drop indicates a severe loss of investor confidence, similar scenarios have drastically affected biotech stocks in the past, especially when pivotal approvals are delayed or challenged.

How important is it?

The article's focus on regulatory difficulties directly affects QURE's future, making it highly relevant for investors and analysts.

Why Long Term?

The uncertainty with AMT-130's approval can have prolonged effects on QURE's market perception, potentially affecting future investments and collaborations as seen with similar biotech firms.

Related Companies

NVCRCRISEDIT
RADNOR, Pa., Nov. 14, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of uniQure N.V. (NASDAQ: QURE) (“uniQure”). On November 3, 2025, uniQure issued a press release revealing that the FDA notified the company that data for its AMT-130, an investigational gene therapy for Huntington’s disease, did not provide sufficient evidence to support uniQure’s Biologics License Application (“BLA”) submission. Specifically, uniQure disclosed that the company believes the FDA currently no longer agrees that data from the Phase I/II studies of AMT-130 may be adequate to provide the primary evidence in support of a BLA submission, and that the timing of the BLA submission for AMT-130 is now unclear as a result.   On this news, the price of uniQure’s stock fell over 50%, from a close of $67.69 on October 31, 2025, to close at $34.29 on November 3, 2025. If you are a uniQure investor and would like to learn more about our investigation, please CLICK HERE to fill out our online form or contact Kessler Topaz Meltzer & Check, LLP: Jonathan Naji, Esq. (484) 270-1453 or E-mail at info@ktmc.com. You can also click on the following link or paste it in your browser: https://www.ktmc.com/uniqure-nv-investigation?utm_source=Globe&mktm=PR Please CLICK HERE to view our video or copy and paste this link into your browser: https://youtube.com/shorts/MPTaI5yN0zw?feature=share Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country involving securities fraud, breaches of fiduciary duties and other violations of state and federal law. Kessler Topaz Meltzer & Check, LLP is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world. The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars). For more information about Kessler Topaz Meltzer & Check, LLP, please visit www.ktmc.com. CONTACT: Kessler Topaz Meltzer & Check, LLPJonathan Naji, Esq.280 King of Prussia RoadRadnor, PA 19087(484) 270-1453info@ktmc.com May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.

Related News